Alexander R Slusky

Director Alexander R Slusky sold 40,000 shares of RKLB at $123.60 on 2026-06-02, retaining 334,675 shares; stock now at $110.08, -27.1% from 52-week high.

Director Alexander R Slusky sold 40,000 shares (10.7% of pre-transaction holdings) at $123.60, reducing his stake from 374,675 to 334,675 shares. The sale occurred when RKLB was trading near its 52-week highs and has since declined 27.1% to the current price of $110.08. Examining his execution history at this ticker: Slusky completed four sales on 2026-05-12 that were all well-timed, with 30-day and 90-day returns ranging from +19.6% to +24.7%—meaning the stock fell after those sales, validating the exit timing. This current sale on 2026-06-02 follows immediately after that streak, occurring when the stock was elevated; the subsequent 27.1% decline suggests similar positioning ahead of near-term weakness. Investors should note that RKLB remains unprofitable (net income $-45.0M on quarterly revenue of $200.3M) while trading at a $63.7B market cap, even as annual revenue grew 38.0%.

Director Alexander Slusky sold 60,000 RKLB shares ($8,964,092.00) at $149.10–$150.00; stock now at $122.39 (-19.0% from 52-wk high).

Alexander R Slusky, a Director at Rocket Lab, executed 2 separate sales totaling 60,000 shares for $8,964,092.00 at prices of $149.10 and $150.00 on 2026-05-28, reducing his holdings by 13.8% to 374,675 shares. The sales occurred near the 52-week high of $151.00; the current price of $122.39 is now 19.0% below that peak, and the stock has gained 55.3% over the 30 days since the transaction but fallen from the transaction prices. Slusky's prior trades at this ticker show poor 90-day timing (1 of 5 prior sells were well-timed), and his cross-ticker track record shows average 90-day returns of +8.5% following his sells, indicating he has historically sold before rallies rather than before declines. The company's fundamentals remain under pressure: it reported negative net income of $-45,022,000.00 on quarterly revenue of $200,348,000.00 despite 38.0% annual revenue growth, and remains unprofitable on a full-year basis. The timing and size of this director sale warrant attention given the proximity to the 52-week high and the company's ongoing unprofitability.

RKLB Director Slusky sells 100.0K shares for $11.8M near 52-week high; stock up +83.5% in 30 days

Director Slusky Alexander R sold 100,000 shares of Rocket Lab Corp (RKLB) for $11.8M across multiple transactions on 2026-05-12, with sale prices ranging from $115.05 to $120.01, while the current price sits at $132.55 — +4.2% above the 52-week high of $127.24 following a +83.5% surge in the past 30 days. This sale represents a meaningful reduction from a still-substantial post-transaction holding of 434.7K shares. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 2 prior sells, and his 2 prior trades specifically at RKLB — both sells in December 2024 — showed subsequent 90-day declines of -18.9% and -15.6%, reinforcing a pattern of well-timed exits at this ticker. Rocket Lab remains unprofitable with net income of $-45,022,000.00 on latest-quarter revenue of $200.3M, meaning the stock's $76.7B market cap rests heavily on growth expectations, making this large insider sale during an extended momentum run a signal worth monitoring.

Director Slusky sold 100,000 shares across 2 sales ($2.4M total) at $24.28–$23.00; post-trade holdings 534,675 shares (down 15.8%)

Director Alexander R Slusky executed 2 separate sales totaling 100,000 shares for $2,364,310.00 at prices of $24.28 and $23.00 per share on December 2–3, 2024. The sales occurred as the stock trades at $23.11 current price, near the lower end of a 52-week range of $3.53–$27.28, and after a strong recent rally (+105.4% over 30 days, +280.1% over 90 days). Rocket Lab remains unprofitable on a full-year basis with net income of $-51,939,000.00 on quarterly revenue of $104,808,000.00, though the company achieved +15.9% annual revenue growth. This substantial reduction of Slusky's holdings by 15.8% warrants attention given the timing against both strong recent price momentum and the company's continued path to profitability.